
Results
4
Stocks which the market has priced substantially different to their cash flows, which could imply risk.
4 companies
Grifols
Market Cap: €6.1b
Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
GRF
€10.11
7D
-2.7%
1Y
-21.3%
Almirall
Market Cap: €2.4b
Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
ALM
€10.98
7D
-2.1%
1Y
7.2%
Pharma Mar
Market Cap: €1.3b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€77.70
7D
-3.1%
1Y
-1.5%
Labiana Health
Market Cap: €54.4m
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally.
LAB
€6.55
7D
3.1%
1Y
69.7%